Loading
In 36 selected people with heavily treated colorectal cancer, a circulating tumour cell workflow predicted response with 47.2% overall accuracy and 5.3% specificity. There was no randomised comparison, and the assay was only one part of a complex treatment programme.
This retrospective study selected 36 people with unresectable refractory recurrent rectal cancer or colorectal cancer liver metastases. Drugs for intra-arterial chemotherapy and targeted treatment were chosen using chemosensitivity and gene-expression analyses of cultured circulating tumour cells.
The combined workflow reported 94.1% sensitivity, 5.3% specificity, 47.1% positive predictive value, 50% negative predictive value and 47.2% overall predictive accuracy. The study had no untreated or standard-care comparison group, and the specialised locoregional treatment makes it impossible to isolate the contribution of the assay. RGCC personnel performed the assays and were among the authors.
The study shows that the workflow was technically feasible, but its low specificity and uncontrolled design do not establish reliable treatment prediction or patient benefit.
Shares RGCC International, Circulating tumour cell capture, Functional (ex vivo) drug testing, Liquid biopsy (ctDNA) and the tags rgcc, retrospective.
Shares RGCC International, Circulating tumour cell capture, Liquid biopsy (ctDNA), Colorectal cancer.
Shares RGCC International, Colorectal cancer and the tag rgcc.
Shares Circulating tumour cell capture, Functional (ex vivo) drug testing.
Shares Circulating tumour cell capture, Liquid biopsy (ctDNA).
Shares Circulating tumour cell capture, Liquid biopsy (ctDNA).
Shares Circulating tumour cell capture, Liquid biopsy (ctDNA), Colorectal cancer.
Shares Circulating tumour cell capture, Functional (ex vivo) drug testing, Liquid biopsy (ctDNA).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/